The study will evaluate the company’s Gen-3 Halo headset as an at-home treatment for mild traumatic brain injury.

As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and ...

Otsuka has reported positive interim results from its Phase III trial evaluating sibeprenlimab, a treatment for adults with ...

During IDWeek 2024 in the US, novel antimicrobials in the development pipeline that are poised to make a difference were ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Galderma has reported positive data from a Phase III clinical trial of RelabotulinumtoxinA for treating frown lines and ...